COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:

Leerink Partners 2025 Global Healthcare Conference

Tuesday, March 11, 2025

Jefferies Biotech on the Beach Summit

Wednesday, March 12, 2025

Barclays 27th Annual Global Healthcare Conference

Thursday, March 13, 2025

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

Media Contact:

Cheryl Wheeler

Head of Corporate Communications



EN
04/03/2025

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare ConferenceTuesday, March 11, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Barclays 27th Annual Global Healthcare ConferenceThursday, March 13, 2025 About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of p...

5h / 23m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial R...

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million;...

February 27, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Result...

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...

February 13, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Appoints Nancy S. Lurker to its Board of Directors

Collegium Appoints Nancy S. Lurker to its Board of Directors STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. “Collegium is pleased to welcome Nancy to our Board of Directors,” said Mike Heffernan, Founder and Chairman of the Board of Collegium. “Nancy’s expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed...

February 5, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Provides 2025 Financial Guidance and Business Update

Collegium Provides 2025 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 2024, we executed on our prio...

January 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch